文献速递神经肿瘤

病理证实的IDH突变胶质瘤恶性转化MRI特征

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.
PubMed 文献 · Neuro Oncol · 2025-01-01

回顾性分析64例初诊病理2级IDH突变胶质瘤患者,复发再取样分为病理恶性转化组35例与非恶性转化组29例。对比解剖、弥散及灌注MRI发现,IDHm-A恶性转化组肿瘤体积更大、T2/FLAIR增长更快、nrCBV更高,ADC有降低趋势;IDHm-O组各影像指标无显著差异。多数恶性转化胶质瘤仍无强化。

要点

  • 强化病灶中IDHm-A 81%、IDHm-O 100%为病理恶性转化,但非强化进展者中亦有41%和62%为恶性转化。
  • IDHm-A恶性转化者肿瘤体积更大、T2/FLAIR增长更快、nrCBV更高(P=.003、.002)。
  • IDHm-O恶性转化与非恶性转化者间增长速率、ADC、nrCBV及球形度均无显著差异(P>.05)。

核心结论

  • 许多病理恶性转化的IDH突变胶质瘤在进展时仍无强化。
  • IDHm-A的恶性转化与非恶性转化在增长速率、弥散和灌注MRI上存在差异,而IDHm-O无显著差异,可能反映两种分子亚型生物学不同并需分别的影像标志物。
  • 肿瘤体积有助于判断两种亚型的恶性转化。

研究设计与样本

  • 回顾性研究纳入64例初诊病理2级IDH突变胶质瘤并接受再次组织取样者,分为病理恶性转化35例与非恶性转化29例。
  • 可用术前解剖MRI 64例、弥散加权MRI 61例、动态磁敏感对比灌注MRI 53例。

主要发现

  • 强化IDHm-A中81%、强化IDHm-O中100%为病理恶性转化;非强化进展者中IDHm-A 41%、IDHm-O 62%为恶性转化。
  • IDHm-A恶性转化组肿瘤体积显著大于非恶性转化组(P=.02),IDHm-O亦然(P=.04)。
  • IDHm-A恶性转化组T2/FLAIR肿瘤体积增长速率显著更高(P=.003)、nrCBV显著更高(P=.002)、ADC有降低趋势(P=.06)。
  • IDHm-O恶性转化与非恶性转化组间增长速率、ADC、nrCBV及球形度均无显著差异(P>.05)。

临床怎么用

  • 对IDHm-A进展期患者,可结合T2/FLAIR增长速率、nrCBV及ADC趋势辅助判断恶性转化。
  • 对IDHm-O进展期患者,现有增长速率、弥散及灌注指标无法可靠区分恶性转化,需依赖组织取样。
  • 两亚型均可参考肿瘤体积辅助判断恶性转化,且不应因无强化而排除恶性转化。

局限性

  • 回顾性设计且样本量有限(总64例,灌注MRI仅53例可用)。
  • 仅纳入初诊病理2级并接受再次取样者,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study explored MRI characteristics at the time of tumor progression to study pathologically confirmed MT in IDHm 1p/19q-intact astrocytomas (IDHm-A) and IDHm 1p/19q-co-deleted oligodendrogliomas (IDHm-O). METHODS: N = 64 patients with initial pathological grade 2 IDH-mutant glioma diagnosis who underwent repeated tissue sampling and were classified as pathologically confirmed MT (n = 35) or non-MT (n = 29) with available presurgical anatomical (n = 64), diffusion-weighted (n = 61), and dynamic susceptibility contrast perfusion MRI (n = 53) were retrospectively studied. Measurable contrast enhancement (> 1000 mm3), tumor volume, tumor growth rate, sphericity, median apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) were compared between MT vs non-MT IDHm-A and IDHm-O. RESULTS: 81% of contrast-enhancing IDHm-A and 100% of contrast-enhancing IDHm-O demonstrated MT, while 41% of IDHm-A and 62% IDHm-O exhibited both nonenhancing tumor progression and MT. Tumor volumes were significantly larger in patients with MT compared to non-MT groups for IDHm-A (P = .02) and IDHm-O (P = .04). T2/FLAIR tumor volume growth rate was significantly higher (P = .003), nrCBV was significantly higher (P = .002), and ADC trended lower (P = .06) in MT vs non-MT IDHm-A. There were no significant differences in growth rate, ADC, nrCBV, or sphericity when comparing MT vs non-MT IDHm-O (P > .05). CONCLUSIONS: Many MT IDHm gliomas remain nonenhancing. Growth rate, diffusion, and perfusion MRI show differences between MT and non-MT in IDHm-A but not IDHm-O, which may reflect the different tumor biology of these IDHm molecular subtypes and their need for separate imaging biomarkers. Tumor volumes can help determine MT for both IDHm-A and IDHm-O.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Cho NS, Le VL, Teraishi A, et al. Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas. Neuro Oncol. 2025. PMID: 40888039. doi:10.1093/neuonc/noaf171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。